Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2003
02/11/2003CA2205274C Novel 2,3 disubstituted-(5,6)-heteroarylfused-pyrimidine-4-ones
02/11/2003CA2176223C Fenbendazole formulations
02/11/2003CA2174529C Dna encoding a hypothalamic atypical neuropeptide y/peptide yy receptor (y5) and uses thereof
02/11/2003CA2151564C Monomeric insulin analog formulations
02/11/2003CA2125476C 20-methyl-substituted vitamin d derivatives
02/11/2003CA2110376C Pharmaceutical enema preparation
02/11/2003CA2097078C Diaper rash treatment
02/11/2003CA2094874C Non-antibacterial tetracycline compositons possessing antiplaque properties
02/11/2003CA2092305C Compounds having antihypertensive and anti-ischemic properties
02/11/2003CA2085584C Treatment of chronic renal failure with imidazole angiotensin-ii receptor antagonists
02/11/2003CA2078670C Compositions and methods for treatment of acne vulgaris and retardation of ageing
02/11/2003CA2071375C Heterocyclic derivatives
02/11/2003CA2070877C Re-formulated diamox sustets
02/11/2003CA2047237C Chroman derivatives
02/11/2003CA2043229C Pyrido[3,4-b]pyrrolo[1,2-e] [1,4,5]oxadiazepines and related analogs, a process for their preparation and their use as medicaments
02/11/2003CA2041818C Separation of enantiomers of cimaterol, (-)-cimaterol and the use thereof as pharmaceutical compositions or as performance enhancers
02/11/2003CA2030715C Hexahydro-1h-quino¬4,3,2-ef|¬1,4|benzoxazepines and related compounds, a process and intermediates for their preparation and their use as medicaments
02/11/2003CA2005704C Pneumolysin mutants and pneumococcal vaccines made therefrom
02/10/2003WO2002014320A2 Novel substituted diaryl azepine derivatives as integrin ligands
02/10/2003CA2419078A1 Substituted diaryl azepine derivatives as integrin ligands
02/08/2003CA2396616A1 Modified cdna for high expression levels of factor viii and its derivatives
02/08/2003CA2354932A1 Topical treatment of pain and to promote healing
02/07/2003CA2354743A1 Mitochondrially targeted antioxidants
02/06/2003WO2003010306A1 Viral mutants that selectively replicate in targeted human cancer cells
02/06/2003WO2003010286A2 Nucleic acids, polypeptides, and methods for modulating apoptosis
02/06/2003WO2003010284A2 Antisense modulation of c-reactive protein expression
02/06/2003WO2003010192A2 An inducer of apoptosis
02/06/2003WO2003010182A1 Novel dammarane sapogenins, their use as anti-cancer agents, and a process for producing same
02/06/2003WO2003010180A1 Methods and compositions for rnai mediated inhibition of gene expression in mammals
02/06/2003WO2003010173A1 Stabilized derivatives of ascorbic acid -3-phosphate
02/06/2003WO2003010170A1 An improved method for preparation of cefuroxime axetil
02/06/2003WO2003010169A1 Antidepressant azaheterocyclylmethyl derivatives of 7, 8-dihydro-6h-5-oxa-1-aza-phenanthrene
02/06/2003WO2003010167A1 8-methoxy-(1,2,4)triazolo(1,5-a)pyridine derivatives and their use as adenosine receptor ligands
02/06/2003WO2003010166A1 Novel 2h-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient
02/06/2003WO2003010164A1 Arylsulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors
02/06/2003WO2003010163A1 Novel compounds
02/06/2003WO2003010161A1 S-6-hydroxy-buspirone
02/06/2003WO2003010159A1 Piperidine derivatives as nmda receptor antagonists
02/06/2003WO2003010158A1 Novel compounds
02/06/2003WO2003010150A1 Polymorph salt of a pyridazinone derivative for the treatment of arrythmia
02/06/2003WO2003010146A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof
02/06/2003WO2003010141A2 Hepatitis c virus polymerase inhibitors with a heterobicyclic structure
02/06/2003WO2003010140A2 Hepatitis c virus polymerase inhibitors with heterobicyclic structure
02/06/2003WO2003010139A2 Antisense modulation of hormone-sensitive lipase expression
02/06/2003WO2003010138A2 Piperidine derivatives as antibacterial agents
02/06/2003WO2003010135A1 Novel phenylpropionic acid derivatives
02/06/2003WO2003010132A1 N-[(1-dimethylaminocycloalkyl)methyl]benzamide derivatives
02/06/2003WO2003010129A1 Process for the preparation of (r)- or (s)-aminocarnitine inner salt, the salts and derivatives thereof
02/06/2003WO2003009897A1 Medicament inhibiting sodium/calcium exchange system
02/06/2003WO2003009881A2 Novel targeted delivery system for bioactive agents
02/06/2003WO2003009872A1 Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient
02/06/2003WO2003009871A2 Inhibitors of plasminogen activator inhibitor for decreasing body mass
02/06/2003WO2003009867A1 Use of biologically active hiv-1 tat, fragments or derivates thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases
02/06/2003WO2003009856A1 Cervical softener
02/06/2003WO2003009855A2 Organo-phosphorous compounds for activating gamma/delta t cells
02/06/2003WO2003009854A1 Lipid lowering composition comprising carnitine and phytosterol
02/06/2003WO2003009853A1 Methods for preventing antipsychotic-induced weight gain
02/06/2003WO2003009849A1 Process for the preparation of 2-(2-(4-(bis(4-fluorophenyl)methyl)-piperazin-1-yl)ethoxy)acetic acid derivatives or corresponding salt forms thereof and intermediates therefor
02/06/2003WO2003009848A1 Use of nk-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses
02/06/2003WO2003009847A1 Substituted piperidines as modulators of the melanocortin receptor
02/06/2003WO2003009846A1 Novel substituted benzimidazole dosage forms and method of using same
02/06/2003WO2003009845A1 Substituted urea neuropeptide y y5 receptor antagonists
02/06/2003WO2003009844A1 Use of thiazole deirvatives for the manufacture of a medicament for the treatment of chronic obstructive pulmonary disease
02/06/2003WO2003009843A1 Use of thiazole derivatives for preparing a medicine for protecting mitochondria
02/06/2003WO2003009842A1 Injectable galenic formulation for use in a diagnosis or a photodynamic therapy and method for preparing same
02/06/2003WO2003009841A1 Novel pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine
02/06/2003WO2003009840A1 Composition comprising at least one lipase inhibitor and carnitine
02/06/2003WO2003009839A1 Benzofuranes and their use in the treatment of atrial fibrillation
02/06/2003WO2003009838A1 Use of stilbene compounds in preparing medicaments for treating or preventing diabetes and diseases associated with retrovirus
02/06/2003WO2003009837A2 Treatment of vascular events in diabetics using lipid-modifying compositions
02/06/2003WO2003009836A2 New uses for 2-amino-2-propane-1,3-diols
02/06/2003WO2003009835A2 Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
02/06/2003WO2003009833A1 Sustained release delivery system
02/06/2003WO2003009831A1 Compositions containing sustained-release fine grains for tablets quickly disintegrable in the oral cavity and process for producing the same
02/06/2003WO2003009830A1 Coated granules of allylamine- or benzylamine-anti-mycotics
02/06/2003WO2003009828A1 Modifying the fatty acid composition of cell membranes of organs and tissues
02/06/2003WO2003009820A2 Methods for promotion of hair growth comprising topical application of prostaglandin analogues
02/06/2003WO2003009809A2 Cancer treatment with gö6976 and its related compounds
02/06/2003WO2003009808A2 Methods, compositions and kits relating to chitinases and chitinase-like molecules and inflammatory disease
02/06/2003WO2003009807A2 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods
02/06/2003WO2003009805A2 Analgesic methods using endothelin receptor ligands
02/06/2003WO2003009800A1 Sustained-release therapeutic bioadhesive systems
02/06/2003WO2003009779A2 Delivery of therapeutic capable agents
02/06/2003WO2003009778A2 Methods and devices for delivery of therapeutic capable agents with variable release profile
02/06/2003WO2003009777A2 Delivery of therapeutic capable agents
02/06/2003WO2003009775A2 Method for reducing myocardial cell damage by regional beta blocker therapy
02/06/2003WO2003009741A2 Methods for treating joint inflammation, pain, and loss of mobility
02/06/2003WO2003009708A1 Milk product comprising unesterified sterol
02/06/2003WO2003009704A2 Enteral compositions for the prevention and/or treatment of sepsis
02/06/2003WO2003009702A1 Animal feed with antimicrobial reactive oxygen species
02/06/2003WO2003009701A1 Animal feed with low pufa concentration
02/06/2003WO2003009700A1 Coccidiostats
02/06/2003WO2003009699A2 Composition comprising cysteamine for specific use in poultry raising and egg production
02/06/2003WO2003009689A1 Methods and compositions for treating fungal infections
02/06/2003WO2003000256A9 Substituted oxazolidinones for combinational therapy
02/06/2003WO2002096433A9 Methods for treating delirium using glucocorticoid receptor-specific antagonists
02/06/2003WO2002096423A3 Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways
02/06/2003WO2002096420A3 Method for treating nerve injury caused by surgery
02/06/2003WO2002095034A3 A retinoic acid metabolizing cytochrome p450
02/06/2003WO2002092772A3 Antisense modulation of ptp1b expression
1 ... 5568 5569 5570 5571 5572 5573 5574 5575 5576 5577 5578 5579 5580 5581 5582 5583 5584 5585 5586 5587 5588 ... 7860